Single-fraction high-dose-rate brachytherapy: a scoping review on outcomes and toxicities for all disease sites.

Authors:
Kazemi M; Nadarajan S; Kamrava M.

Journal:
J Contemp Brachytherapy

Publication Year: 2022

DOI:
10.5114/jcb.2022.121477

PMCID:
PMC9720691

PMID:
36478697

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Contemp Brachytherapy

Abbreviation: J Contemp Brachytherapy

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Radiology, Nuclear Medicine & Medical Imaging

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
3D-printed vaginal cylindrical template with curved needle channels in MRI-guided vaginal cuff brac…
Mao Z; Zhao H. (2023) - Transparency Score: 3/6
Advanced non-melanoma skin cancer in elderly patients: When surgery says NO, interventional radioth…
Chicheł A; Chyrek AJ; Kluska A and 1 more (2023) - Transparency Score: 2/6
Analysis of source dwell position during treatment in brachytherapy using CT scout images.
Nakajima N; Isobe T; Furuyama Y and 9 more (2023) - Transparency Score: 3/6
Assessment of dose to vaginal mucosa for gynecologic template interstitial high-dose-rate brachythe…
Elburg DV; Meyer T; Martell K and 2 more (2023) - Transparency Score: 3/6
A study comparing baseline and best-corrected visual acuity after iodine-125 episcleral brachythera…
Miguel D; de Frutos JM; Alonso P and 5 more (2023) - Transparency Score: 2/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure Dr. Mitchell Kamrava, MD, MHDS have conflicts of interest. ABS board of directors’ member at large, ADROP board of directors’ member at large, advisory board fees Theragenics Corp., DSMB GammaTile, Alessa, and Book Royalties Springer. The other authors report no conflict of interest."

Funding Disclosure
Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025